Tag: IL-17

Targeting IL-17A offers a promising treatment perspective in hidradenitis suppurativa

Presented By
Dr Kim Papp, Probity Medical Research, Canada
Trial
Phase 3
Conference
EADV 2024
Type
Peer-reviewed article

6 November 2024 13:26

Bimekizumab shows sustained 2-year efficacy in hidradenitis suppurativa

Presented By
Prof. Christos Zouboulis, Dessau Medical Center, Germany
Trial
BE HEARD
Conference
EADV 2024
Type
Peer-reviewed article

6 November 2024 13:22

PsoBest registry: Biologics dominate treatment for moderate-to-severe psoriasis

Presented By
Prof. Matthias Augustin, University Medical Center Hamburg-Eppendorf, Germany
Trial
PsoBest registry
Conference
EADV 2024
Type
Peer-reviewed article

6 November 2024 12:23

Dual IL-17A/F blocker significantly reduces spinal radiographic progression in radiographic axSpA

Presented By
Prof. Xenofon Baraliakos, Ruhr-University Bochum, Germany
Trial
Phase 3, BE MOBILE 2
Conference
EULAR 2024
Type
Peer-reviewed article

29 July 2024 14:38

Small protein targeting IL-17A effective in PsA management

Presented By
Prof. Philip Mease, University of Washington; Swedish Medical Center, WA, USA
Trial
Phase 2
Conference
EULAR 2024
Type
Peer-reviewed article

29 July 2024 14:37

How close are we to personalised medicine in psoriatic arthritis?

Presented By
Prof. Ennio Lubrano, University of Molise, Ital
Conference
IFPA 2024
Type
News article

17 July 2024 14:38

Depression complicates the management of psoriatic disease

Presented By
Dr Wiebke Sondermann, University Hospital Essen, Germany
Conference
IFPA 2024
Type
News article

17 July 2024 14:20

The unfavourable role of obesity in psoriatic disease

Presented By
Prof. Ulrich Mrowietz, University Medical Center Schleswig-Holstein, Germany
Conference
IFPA 2024
Type
News article

17 July 2024 14:13

Multiple novel oral agents show promise in psoriasis

Presented By
Prof. April Armstrong, University of California Los Angeles, USA
Trial
FRONTIER; STRIDE
Conference
IFPA 2024

17 July 2024 14:04

Biologics in psoriatic arthritis: where we are and where we are headed

Presented By
Dr Vinod Chandran
Conference
IFPA 2024
Type
News article

17 July 2024 11:55

IL-23 blockers may lower the risk of developing inflammatory and psoriatic arthritis

Presented By
Prof. Bruce Strober, Yale University School of Medicine, USA
Conference
EADV 2023
Type
Peer-reviewed article

28 November 2023 12:01

Anti-IL17 blockade leads to maintained pain reduction in patients with HS

Presented By
Dr John Ingram, Cardiff University, UK
Trial
Phase 3, SUNSHINE; SUNRISE
Conference
EADV 2023
Type
Peer-reviewed article

28 November 2023 11:44

Switching to risankizumab successful in IL-17 inhibitor non-responders

Presented By
Prof. Richard Warren, University of Manchester, UK
Trial
Phase 3, aIMM study
Conference
AAD 2023
Type
Peer-reviewed article

15 May 2023 11:56

Bimekizumab: Robust 1-year results in treating psoriatic arthritis

Presented By
Prof. Christopher Ritchlin, University of Rochester Medical Center, USA
Trial
Phase 3
Conference
ACR 2022
Type
News article

1 December 2022 14:33

New treatments for HS: IL-17 inhibitors next in practice?

Presented By
Dr Axel Villani, University of Lyon, France & Prof. Thrasyvoulos Tzellos, Nordland Hospital Trust, Norway
Conference
SPIN 2022
Type
Peer-reviewed article

26 August 2022 10:05

Psoriatic arthritis: significant improvement with bimekizumab

Presented By
Prof. Iain McInnes , Glasgow University, United Kingdom
Trial
Phase 3, BE OPTIMAL
Conference
EULAR 2022
Type
Peer-reviewed article

21 July 2022 14:36

Potential biomarker discovered for treatment response to ustekinumab

Presented By
Mr Shane Solanky, King’s College London, UK
Conference
PFGC 2021
Type
Peer-reviewed article

3 February 2022 15:46

Explaining arthropathy development through IL-4 and IL-13 blockade

Presented By
Dr Charlie Bridgewood, University of Leeds, UK
Conference
PFGC 2021
Type
Peer-reviewed article

3 February 2022 10:51

Patients on immunomodulators need 2 COVID-19 vaccinations before seroconversion

Presented By
Dr Ali Al-Janabi, University of Manchester, UK
Conference
PFGC 2021
Type
Peer-reviewed article

2 February 2022 15:22

IL-17 inhibition showing efficacy in GCA in phase 2 trials

Presented By
Prof. Jens Thiel, Medical University Graz, Austria
Trial
Phase 2, TitAIN
Conference
ACR 2021
Type
Peer-reviewed article

14 January 2022 11:05

Why antipsychotics cause weight gain

Presented By
Prof. Louise Gallagher, University of Dublin, Ireland
Conference
ECNP 2021
Type
Peer-reviewed article

26 November 2021 11:18

Existing and upcoming small molecules in psoriasis

Presented By
Dr Enikö Sonkoly , Karolinska University Hospital, Sweden
Trial
POETYK PSO; PSOARING
Conference
EADV 2021
Type
Peer-reviewed article

18 November 2021 13:19

Active PsA: Biomarkers distinguish radiographic progressors from non-progressors

Trial
Phase 3, SPIRIT-P1
Conference
WPPAC 2021
Type
Peer-reviewed article

17 September 2021 13:37

Psoriatic arthritis: Guidelines and best practice

Trial
Phase 3, BE ACTIVE, PATERA
Conference
WPPAC 2021
Type
Peer-reviewed article

17 September 2021 11:19

Psoriasis: New treatments and current pipeline

Presented By
Prof. Kristian Reich, Dermatologikum Hamburg, Germany
Conference
WPPAC 2021
Type
Peer-reviewed article

17 September 2021 11:08

Efficacy and safety of secukinumab in juvenile idiopathic arthritis

Presented By
Dr Nicola Ruperto, IRCCS Istituto G. Gaslini, Italy
Trial
Phase 3, JUNIPERA
Conference
EULAR 2021
Type
Peer-reviewed article

2 August 2021 23:33

Psoriasis and hidradenitis suppurativa during COVID-19: keep calm and carry on

Presented By
Prof. April W. Armstrong, University of Southern California, USA
Conference
AAD VMX 2021
Type
Peer-reviewed article

7 June 2021 13:32

Psoriasis: The treatment armamentarium continues to grow

Presented By
Prof. Bruce Strober, Yale University, CT, USA
Conference
AAD VMX 2021
Type
Peer-reviewed article

7 June 2021 13:32

IL-17 inhibitor effective in axial manifestations of psoriatic arthritis

Trial
Phase 3, MAXIMISE
Conference
AAD VMX 2021
Type
Peer-reviewed article

7 June 2021 13:00

Promising results with nanobody treatment in psoriasis

Presented By
Dr Kim A. Papp, Probity Medical Research, Canada
Trial
Phase 2
Conference
EADV 2020
Type
Peer-reviewed article

17 December 2020 13:40

Efficacious non-steroidal topical for psoriasis

Presented By
Prof. Mark Lebwohl, Icahn School of Medicine at Mount Sinai, USA
Trial
Phase 3, PSOARING
Conference
EADV 2020
Type
Peer-reviewed article

17 December 2020 13:28

AxSpA real-life remission rates higher on biologics

Presented By
Dr Charlotte Baert, Saint Luc University Hospital, Belgium
Conference
EULAR 2020
Type
Peer-reviewed article

14 August 2020 10:24

IL-17A and IL-17F blockade remarkably effective in psoriasis

Presented By
Prof. Kristian Reich; Prof. Kenneth B. Gordon
Trial
BE VIVID and BE READY
Conference
AAD 2020
Type
Peer-reviewed article

6 August 2020 07:09

Novel IL-23 blocker risankizumab highly effective and tolerable in psoriasis

Presented By
Prof. Richard B. Warren
Trial
IMMerge
Conference
AAD 2020
Type
Peer-reviewed article

6 August 2020 07:07

IL-17A blocker effective in paediatric psoriasis patients

Presented By
Dr Kim Papp, Probity Medical Research, Canada
Trial
Phase 3, IXORA-PEDS
Conference
EADV 2019
Type
Peer-reviewed article

9 December 2019 20:51

No hint of teratogenicity through ixekizumab

Presented By
Prof. Alexander Egeberg, Herlev and Gentofte Hospital, Denmark
Trial
PSOLAR
Conference
EADV 2019
Type
Peer-reviewed article

9 October 2019 14:32

Efficacy and safety of bimekizumab in patients with active PsA

Presented By
Dr Christopher Ritchlin, University of Rochester Medical Centre, USA
Trial
Phase 2, BE ACTIVE
Conference
EULAR 2019
Type
Peer-reviewed article

4 September 2019 11:10

Biologicals beyond TNF blockade

Presented By
Prof. Brian Kirby, St. Vincent’s University Hospital, Ireland
Conference
WCD 2019
Type
Peer-reviewed article

26 August 2019 11:11

Registries – an important research tool in biologics

Presented By
Prof. Bruce E. Strober, UConn Health, USA
Conference
WCD 2019
Type
Peer-reviewed article

26 August 2019 10:10

Advances in target-oriented therapy: psoriatic arthritis

Presented By
Prof. Wolf-Henning Boehncke, University of Geneva, Switzerland
Trial
ECLIPSA, TICOPA
Conference
SPIN 2019
Type
Peer-reviewed article

21 June 2019 23:48

Understanding genetics to unravel psoriasis and atopic dermatitis pathogenesis

Presented By
Prof. Jonathan Barker, Kings College London, United Kingdom
Conference
SPIN 2019
Type
Peer-reviewed article

21 June 2019 20:34

Results from the ECLIPSE trial: does blocking IL-23 have better long-term outcomes in psoriasis?

Presented By
Prof. Kristian Reich, Georg-August-University Göttingen, Germany
Trial
ECLIPSE
Conference
SPIN 2019
Type
Peer-reviewed article

21 June 2019 18:23

Atopic dermatitis and psoriasis: on a spectrum?

Presented By
Prof. Emma Guttman-Yassky, Mount Sinai Medical School, USA
Conference
SPIN 2019
Type
Peer-reviewed article

21 June 2019 13:39

IBD risk of treatment with IL-17 antagonists

Presented By
Dr Wolfgang Eigner, Medical University of Vienna, Austria
Conference
ECCO 2019
Type
Peer-reviewed article

9 May 2019 14:37

Secukinumab maintains improvements in psoriasis through 5 years of treatment

Presented By
Prof. Richard Langley, Dalhousie University, Canada
Trial
ERASURE/FIXTURE
Conference
AAD 2019
Type
Peer-reviewed article

19 April 2019 23:10

Dual IL-17A and IL-17F blocker leads to unprecedented response rates in psoriasis

Presented By
Dr Andrew Blauvelt, Oregon Medical Research Center, USA
Trial
BE ABLE
Conference
AAD 2019
Type
Peer-reviewed article

19 April 2019 19:24

Psoriasis and Biologics: The Beat Goes On

Presented By
Prof. Mark Lebwohl, Mount Sinai School of Medicine, USA
Conference
AAD 2019
Type
Peer-reviewed article

19 April 2019 14:06
site created by:   

© 2024 Medicom Medical Publishers.  All rights reserved. Terms and Conditions | Privacy Policy



HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com